KWAKU OPPONG: Open Payments
NPI 1194210021 · HAZLEHURST, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$590 in 24 payments from 9 companies in 2025. Trend: 2023 $84 · 2024 $105 · 2025 $590
Food & beverage: $590
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $262 |
| ABBVIE INC. | 5 | $101 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Neos Therapeutics, LP | 1 | $19 |
| Almatica Pharma LLC | 1 | $15 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, Qelbree, Auvelity, REXULTI, UZEDY, Adzenys XR-ODT, LOREEV XR.
Industry payments across GA — which companies pay providers there.
